menu
    • menu
    [{"orgOrder":0,"company":"Morningside Pharmaceuticals","sponsor":"Aspire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Gestodene","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Morningside Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Morningside Pharmaceuticals \/ Aspire Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Morningside Pharmaceuticals \/ Aspire Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Morningside Pharmaceuticals

    Menu

    Morningside Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Morningside Pharmaceuticals

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed

                            Morningside Pharmaceuticals

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gestodene,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Aspire Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            H.I.G. Capital Acquires Morningside Healthcare and Morningside Pharmaceuticals

                            Details : The combination will create one of the largest and fastest growing UK pharma companies and accelerated growth in current and future product portfolio, especially in healthcare (leading asset Akizza having gestodene/ethinylestradiol combination) in the UK...

                            Brand Name : Akizza

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 03, 2022

                            Lead Product(s) : Gestodene,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Aspire Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth